Taracena PS, Rodriguez WFL, Díaz GEJ, Guzmán VG

Language: Spanish
References: 19
Page: 12-17
PDF size: 198.12 Kb.

ABSTRACT

Introduction: recommendations call for maintaining 100-180 mg/dL serum glucose for non-critically ill patients in most settings; however, the methods for achieving these figures and the evidence supporting these recommendations are conflicting. As for the pharmacological method of control, insulin remains the first choice, although the methods of administering insulin are heterogeneous in different non-critical clinical settings. Whether bolus or basal-bolus administration scheme, the available literature maintains conflicting results. Materials and methods: in a retrospective, non-randomized, descriptive, comparative study, the incidence of hypoglycemia in two treatments for hyperglycemia control was documented to identify which has a higher risk of generating hypoglycemia in non-critical patients. Forty cases were analyzed, documenting the type of insulin regimen, demographic characteristics, and incidence of hypoglycemia. Results: more hypoglycemia events were recorded between the two groups in the basal-bolus vs. bolus group (21.5 versus 7.69%, p ‹ 0.05). Conclusions: the data analysis suggests a higher risk of hypoglycemia in non-critically ill patients in the basal-bolus schedule, but the authors are confident that the experience gained with this protocol will allow the application of prospective studies in the future.

REFERENCES

1. Basto-Abreu A, López-Olmedo N, Rojas-Martínez R, Aguilar-SalinasCA, Moreno-Banda GL, Carnalla M et al. Prevalencia de prediabetesy diabetes en México: Ensanut 2022. Salud Pública Mex. 2023; 65:s163-s168.

2. Pasquel FJ, Lansang MC, Dhatariya K, Umpierrez GE. Managementof diabetes and hyperglycaemia in the hospital. Lancet DiabetesEndocrinol. 2021; 9 (3): 174-188.

3. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, BruemmerD. et al 16. Diabetes care in the hospital: standards of care indiabetes-2023. Diabetes care. 2023; 46 (Suppl 1): S267-S278.

4. Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, MaruthurNM et al. Management of hyperglycemia in type 2 diabetes, 2022.A consensus report by the American Diabetes Association (ADA) andthe European Association for the Study of Diabetes (EASD). DiabetesCare. 2022; 45 (11): 2753-2786.

5. Lorenzo-González C, Atienza-Sánchez E, Reyes-Umpierrez D,Vellanki P, Davis GM, Pasquel FJ et al. Safety and efficacy of DPP-4inhibitors for the management of hospitalized general medicine andsurgery patients with type 2 diabetes. Endocr Pract. 2020; 26 (7):722-728.

6. Jervis M, Mitchell AP, Islam N, Mustafa OG, Kelly PA, Whyte MB.GLP-1 receptor agonist use during hospitalisation: Better glycaemiccontrol compared to premixed insulin. Diabetes Metab Res Rev. 2022;38 (8): e3574.

7. Estrada AK, Delgado-Maldonado T, Lara-Ramírez EE, Martínez-Vázquez AV, Ortiz-Pérez E, Paz-González AD et al. Recent advancesin the development of type 2 sodium-glucose cotransporter inhibitorsfor the treatment of type 2 diabetes mellitus. Mini Rev Med Chem.2022; 22 (4): 586-599.

8. Van den Berghe G, Wouters P, Weekers F, Verwaest C, BruyninckxF, Schetz M et al. Intensive insulin therapy in critically ill patients. NEngl J Med. 2001; 345 (19): 1359-1367.

9. NICE-SUGAR Study Investigators, Finfer S, Chittock DR, Su SY, BlairD, Foster D et al. Intensive versus conventional glucose control incritically ill patients. N Engl J Med. 2009;360:1283-1297.

10. Said E, Farid S, Sabry N, Fawzi M. Comparison on efficacy andsafety of three inpatient insulin regimens for management of noncriticalpatients with type 2 diabetes. Pharmacol Pharm. 2013; 4(7): 556-565.

11. Schroeder JE, Liebergall M, Raz I, Egleston R, Ben Sussan G, PeyserA et. al. Benefits of a simple glycaemic protocol in an orthopaedicsurgery ward: a randomized prospective study. Diabetes Metabol ResRev. 2012; 28 (1): 71-75.

12. Aidar RG, Salil G, Sundae S, Limin P, Umpierrez GE. Managementof hyperglycemia in diabetic patients with hematologic malignanciesduring dexamethasone therapy. Endocr Pract. 2013; 19 (2): 231-235.

13. Webster RE, Belfer JJ, Schmidt KJ. Evaluation of basal plus versussliding scale insulin therapy on glucose variability in critically illpatients without preexisting diabetes. Ann Pharmacother. 2024; 58(6): 565-571.

14. Cheung NW, Chipps DR. Sliding scale insulin: will the false idol finallyfall? Intern Med J. 2010; 40 (9): 662-664.

15. Umpierrez GE, Smiley D, Zisman A, Prieto LM, Palacio A, CeronM et al. Randomized study of basal-bolus insulin therapy in theinpatient management of patients with type 2 diabetes (RABBIT 2trial). Diabetes Care. 2007; 30 (9): 2181-2186.

16. Umpierrez GE, Smiley D, Jacobs S, Peng L, Temponi A, Mulligan P,Umpierrez D, Newton C, Olson D, Rizzo M. Randomized study ofbasal-bolus insulin therapy in the inpatient management of patientswith type 2 diabetes undergoing general surgery (RABBIT 2 surgery).Diabetes Care. 2011 Feb;34(2):256-61.

17. Lee YY, Lin YM, Leu WJ, Wu MY, Tseng JH, Hsu MT et al. Sliding-scaleinsulin used for blood glucose control: a meta-analysis of randomizedcontrolled trials. Metabolism. 2015; 64 (9): 1183-1192.

18. Colunga-Lozano LE, Torres FJ, Delgado-Figueroa N, Gonzalez-Padilla DA, Hernandez AV, Roman Y et al. Sliding scale insulin fornon-critically ill hospitalised adults with diabetes mellitus. CochraneDatabase Syst Rev. 2018; 11 (11): CD011296.

19. Vellanki P, Cardona S, Galindo RJ, Urrutia MA, Pasquel FJ, Davis GMet al. Efficacy and safety of intensive versus nonintensive supplementalinsulin with a basal-bolus insulin regimen in hospitalized patients withtype 2 diabetes: a randomized clinical study. Diabetes Care. 2022;45 (10): 2217-2223.